| 5.59 0.21 (3.9%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.97 | 1-year : | 8 |
| Resists | First : | 5.97 | Second : | 6.84 |
| Pivot price | 5.57  |
|||
| Supports | First : | 4.55 | Second : | 3.78 |
| MAs | MA(5) : | 5.43 |
MA(20) : | 5.72 |
| MA(100) : | 5.05 |
MA(250) : | 4.76 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.9 |
D(3) : | 37.4 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 8.51 | Low : | 2.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMDX ] has closed below upper band by 49.1%. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.68 - 5.7 | 5.7 - 5.72 |
| Low: | 5.39 - 5.41 | 5.41 - 5.44 |
| Close: | 5.55 - 5.58 | 5.58 - 5.63 |
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Sun, 21 Jun 2026
IMDX SEC Filings - Insight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Fri, 19 Jun 2026
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Yahoo Finance
Wed, 17 Jun 2026
Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase - Stock Titan
Tue, 16 Jun 2026
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 1.008e+007 (%) |
| Held by Institutions | 20.1 (%) |
| Shares Short | 713 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.257e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -32 % |
| Return on Assets (ttm) | 284.3 % |
| Return on Equity (ttm) | -43.3 % |
| Qtrly Rev. Growth | 1.95e+006 % |
| Gross Profit (p.s.) | 0.07 |
| Sales Per Share | 0.12 |
| EBITDA (p.s.) | -0.88 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 44.4 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 1.28e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|